LMNX Luminex Corporation

AUSTIN, Texas, Sept. 14 /PRNewswire-FirstCall/ -- Luminex Corporation (NASDAQ:LMNX) today announced it will be presenting at the UBS Global Life Sciences Conference in New York on September 28, 2005. Patrick J. Balthrop, President and Chief Executive Officer of Luminex will be speaking to institutional investors at 12:00 p.m. Eastern Time. A live webcast of the presentation can be accessed via the "Conferences" link at http://www.ibb.ubs.com/ , or the "Investor Relations" link on the Company's website, at http://luminexcorp.com/ . A replay of the webcast will also be archived on the Company's website for 90 days. Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ . Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Contact: Harriss T. Currie Vice President, Finance Chief Financial Officer 512.219.8020 DATASOURCE: Luminex Corporation CONTACT: Harriss T. Currie, Vice President, Finance, Chief Financial Officer of Luminex Corporation, +1-512-219-8020, or Web site: http://www.luminexcorp.com/ http://www.ibb.ubs.com/

Copyright